Endothelin-1 (EDN1) has been reported to be implicated in the pathophysiology of asthma. Literature results on the genetic association of EDN1 in asthma are inconsistent. Eleven single nucleotide polymorphisms in EDN1 were genotyped in 342 and 100 families from UK and Norway, respectively. Asthma, bronchial hyperreactivity (BHR) and atopic asthma phenotypes were analyzed for the family-based association. Five single nucleotide polymorphisms (SNPs) were associated with asthma (0.0017pPp0.0291), five with BHR (0.0026pPp0.0315) and three with atopic asthma (0.0016pPp0.041) in the UK population. Three SNPs were associated with asthma (0.0041pPp0.019), seven with BHR (0.0018pPp0.041) and two with atopic asthma (0.0123pPp0.0153) in the Norwegian population. A polymorphism (rs1800541) in the promoter region of EDN1 was replicated in the two populations. A nonsynonymous coding polymorphism (rs5370) resulting in a change of amino acid Asn to Lys at position 198 was also replicated. The results of haplotype-based association analyses strongly supported the ones of single SNP associations. This study demonstrates the significant evidence of association between polymorphisms in EDN1 and asthma.
Introduction
Asthma is a common and heterogeneous respiratory disease characterized by variable airway obstruction, bronchial hyperreactivity (BHR) and airway inflammation. 1 The development of asthma appears to be determined by gene-gene interactions and gene-environment interactions. 2 Endothelin-1 (ET-1 or EDN1), is one of three isoforms of human endothelin (ET), a 21-amino acid peptide originally isolated from endothelial cells. 3, 4 An abundant body of evidence has emerged implicating ET-1 in a range of diseases due to its vasoconstrictory, profibrotic and proinflammatory properties. 5 The diverse functional effects of EDN1 in various systems are mediated via two populations of G proteincoupled receptors, ET A (EDNRA) 6 and ET B (EDNRB).
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EDN1 and its receptors are present in mammalian lung, including humans, and there is accumulating evidence suggesting a role for EDN1 in the pathophysiology of asthma. For example, EDN1 increases mucus secretion, contracts bronchial smooth muscle, enhances release of proinflammatory mediators and stimulates pulmonary fibroblasts to produce collagen. [8] [9] [10] In addition, enhanced expression and increased levels of EDN1 have been demonstrated in the lungs of patients with asthma compared with nonasthmatic individuals. [11] [12] [13] The potency of EDN1 in eliciting contraction in bronchial smooth muscle from asthmatic subjects is significantly lower than in airways of normal subjects, perhaps reflecting subsensitivity due to exposure of asthmatic airways to enhanced EDN1 levels. 14, 15 Genome-wide linkage searches for asthma have identified linked regions on 6p where EDN1 gene is located. [16] [17] [18] Therefore, the genetic variations at the EDN1 may confer susceptibility to asthma phenotypes.
One report evaluating EDN1 variants in two asthma populations (UK and Japanese case-control populations with 300 and 200 subjects, respectively) failed to demonstrate the evidence of association with asthma, atopy or total serum IgE levels based on one marker genotyped in EDN1 gene. 19 A second study in a Caucasian population with 97 families demonstrated weak association of one EDN1 variant with asthma with a marginally significant P-value (P ¼ 0.044), but not with other phenotypes from one marker genotyped. 20 A third study in a Czech population with 270 cases and controls demonstrated the association of one EDN1 variant with total IgE, but it was not replicated with asthma and atopy from two markers genotyped. 21, 22 Based on limited genotyping information, these three genetic association studies did not provide conclusive evidence that EDN1 is associated with asthma-related phenotypes. Moreover, the inconsistency of these data may be due to false positive/negative results, population stratification or true variability in association among different populations due to heterogeneous disease variants. 23 These studies did not evaluate BHR which may be a key phenotype based on the known pathophysiology of asthma. Here, we present our comprehensive evaluation of EDN1 variants in a family-based association study by investigating a large UK population with 342 families and 1446 subjects and a replication population from Norway with 100 families. Our results suggest that genetic variants in EDN1 affect the asthma-related phenotypes.
Results

Single nucleotide polymorphism association analysis
The location and characteristics of single nucleotide polymorphisms (SNPs) from the EDN1 are summarized in Table 1 . Results of SNP association analysis are shown in Table 2 . We detected significant associations across EDN1 gene in the two populations. From the eleven SNPs tested in the UK population, five SNPs were associated with asthma (0.0017pPp0.0291), five SNPs with BHR (0.0026pPp0.0315) and three SNPs with atopic asthma (0.0016pPp0.0410). The associations of SNP 10 (rs5370) with asthma and atopic asthma, and SNPs 1 (rs1800541) and 4 (rs1800543) with BHR were still significant after Bonferroni correction of multiple testing. In the Norwegian population, three of eleven tested SNPs were associated with asthma (0.0041pPp0.0198); seven SNPs were associated with Polymorphisms in the endothelin-1 G Zhu et al BHR (0.0018pPp0.0412); two SNPs with atopic asthma (0.0123pPp0.0153). SNPs 1 (rs1800541), 2 (rs1800542), 9 (rs1630736) and 11 (rs4714383) with BHR were still significant after Bonferroni multiple correction. Several SNPs showed significant replicated associations for the same phenotype in the two populations. SNPs 1 (rs1800541) and 8 (rs1629862) were replicated for asthma in the two populations. SNPs 1 (rs1800541) and 2 (rs1800542) and 10 (rs5370) were replicated for BHR in the two populations. SNP 8 (rs1629862) was replicated for atopic asthma in the two populations. The risk allele was the same in both populations in all these instances. Thus, the direction of the association of these SNPs was the same in both populations. A nonsynonymous SNP 10 (rs5370) was replicated for BHR in the two populations with the same risk allele. SNP 1 (rs1800541) in the promoter region also showed very significant P-values for BHR and asthma in the two populations. Haplotype-based analysis The significant results of haplotype analyses of asthma, BHR and atopic asthma are listed in Table 3 . In the UK population, three risk haplotypes (0.0069pP-globalp0.0306 and 0.0041pP-specific p0.0173) and one protective haplotype (P-global ¼ 0.0370 and P-specific ¼ 0.0255) with a significant test result were detected for the asthma, five risk haplotype (0.0049pP-global p0.0294 and 0.0021pP-specific p0.0258) and one protective haplotype (P-global ¼ 0.0229 and P-specific ¼ 0.0121) for BHR, one risk haplotype (P-global ¼ 0.0376 and P-specific ¼ 0.0290) for atopic asthma. The risk haplotype 6-7-8-9-10 (T-A-G-C-G) with asthma and risk haplotypes 1-2-3-4-5 (T-A-G-T-A) and 3-4-5-6-7 (A-C-A-C-G) with BHR were still significant after Bonferroni correction of multiple testing.
We also detected significant haplotype associations in the Norwegian population (Table 3) . One significant risk haplotype (P-global ¼ 0.0366 and P-specific ¼ 0.0278) was detected for asthma, two risk haplotypes (0.0039p P-globalp0.0051 and 0.0019pP-specific p0.0036) for BHR and one risk haplotype (P-global ¼ 0.0445 and P-specific ¼ 0.0323) for atopic asthma. Particularly, the risk haplotypes 1-2-3-4-5 (T-A-G-T-A) and 6-7-8-9-10 (T-A-G-C-G) for BHR remained significant after Bonferroni correction of multiple testing.
Discussion
To assess the role of EDN1 in asthma-related phenotypes, we conducted family-based studies in the two populations involving 342 UK families and 100 Norwegian families. EDN1 showed significant genetic association in the two populations. Furthermore, we have shown robust evidence of replication for several SNPs in asthma-related phenotypes. Four SNPs in EDN1, SNP 1 (rs1800541), SNP 2 (rs1800542), SNP 8 (rs1629862) and SNP 10 (rs5370) were replicated in the two populations for the same phenotype. The results of haplotype analyses were consistent with the data from single marker analyses.
The most compelling evidence of association was from SNP 1 (rs1800541) and SNP 10 (rs5370) in the EDN1 gene. SNP 1 (rs1800541) is located 1265 bp upstream of the The relative position of the SNPs in the haplotypes combinations corresponds to the SNPs ids given in Table 1 .
b
Haplotypes with a P-global o0.05 are shown.
c P-values marked * are still significant after corrections for multiple testing.
d P-specific represents the P-value of the most significant haplotype. e Haplo_Freq represents the frequency of the most significant haplotype. Polymorphisms in the endothelin-1 G Zhu et al transcription start site and possibly in the promoter region, so it may have function in regulating the transcription of EDN1. SNP 10 (rs5370) is a nonsynonymous coding polymorphism, leading to a change of Lysine to Asparagine at position 198 in EDN1. Lys198 is in a relatively poorly conserved region of the EDN1 propeptide, the amino acid change might affect the processing of preproendothelin, influencing the synthesis of EDN1, however detailed laboratory investigation would be needed to confirm this. This nonsynonymous SNP has already been associated with heart failure and hypertension. 24, 25 It is possible that this variant contributes to asthma susceptibility; however, the impact of other SNPs in LD with SNP 10 (rs5370) should not be excluded. In addition, both SNP 2 (rs1800542) and SNP 4 (rs1800543) are located within 50 bp of splice acceptor sites in EDN1 and potentially impact consensus binding sites for the exonic splicing enhancer, SF2/ASF. 26 Binding by SF2/ASF is likely to favor the selection of weaker alternative splice sites in a gene. Thus, the nature of variation in EDN1 appears to be quite heterogeneous, suggesting the possibility of multiple EDN1 asthma susceptibility alleles, which may act synergistically or independently.
Our study has several strengths over previous studies. [19] [20] [21] First, the number of subjects used in our study is larger than that in three studies previously reported. Relatively small sample size can be a significant contributory factor for the failure to detect and replicate associations across studies. Mao et al. 19 did not detect significant associations between variants of EDN1 gene, and asthma related phenotypes in UK and Japanese populations, which were relatively smaller. Second, our study was based on a family-based design and the significant associations from family studies are robust against population admixture and stratification. Third, we conducted this study by ascertaining the populations from two countries. The genetic associations with the same SNPs for same phenotypes in different populations are more reliable, so our study has an advantage over previously reported studies. Replicating results remains the gold standard for genetic association studies of complex diseases such as asthma. 27 When a gene is replicated, it is often with a different phenotype, with different polymorphisms in the same gene, and even with different alleles of the same variant. 2, 28 Fourth, the most significant single marker and haplotype associations in the two populations were still significant after stringent Bonferroni multiple correction. Thus, the possibility that our results are false positive is greatly reduced. Fifth, the finding that EDN1 was associated with different asthma-related phenotypes makes the results more reliable.
On the other hand, our study has several weaknesses. First, SNPs in EDN1 but not in EDNRA and EDNRB were investigated in our study. Further association analysis of EDNRA and EDNRB may be necessary. Second, SNPs were selected from public databases and not from the LD tagging SNPs of all the SNPs in EDN1 gene of 10.4 kb in HapMap Caucasian data. However, 11 SNPs are evenly distributed in the whole gene-on an average 1 SNP per kb; so these 11 SNPs may capture the most of the genotyping information. Further, putatively functional, significantly associated SNPs were detected and showed that EDN1 was a susceptibility gene for asthma.
In summary, our genetic association studies, including the analyses of the single markers and haplotypes, revealed significant evidence of associations of polymorphisms in EDN1 gene with asthma and BHR. We present evidence that several of the variants in EDN1 may confer a functional impact. Further functional studies are needed to clarify the role of variants of EDN1 in the pathophysiology of asthma.
Materials and methods
Study populations
The subjects involved in this study are from two sets of asthma families.
Primary study population. Three hundred forty-two families ascertained from the United Kingdom as a part of the Genetics of Asthma International Network (GAIN) were selected as a primary study population. The details of the families collected from four centers are as follows: 94 families with 401 subjects from Aberdeen, UK; 73 families with 301 subjects from Leicester, UK; 93 families with 399 subjects from Sheffield, UK; and 82 families with 345 subjects from Stoke-on-Trent, UK. In the selection of these families, at least two siblings with clinical asthma were required. The ascertainment procedure for the GAIN collection is described elsewhere.
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Replication population. A total of 100 families with 414 subjects were ascertained from Norway as a part of GAIN collection served as a replication group. In the selection of these families, at least two siblings with clinical asthma were required. The ascertainment procedure for the collection is described elsewhere. 30 All subjects were evaluated using the standard protocols. Baseline spirometry was performed according to American Thoracic Society criteria. Methacholine challenge test was done with percent-predicted FEV 1 (forced expiratory volume in one second) at 70 or more. A bronchodilator response test was done in those patients whose percent-predicted FEV 1 percent is less than 70. Skin prick tests for common allergens (Dust Mites-D. Pteronyssinus and D. Farinae, dog, cat, grass mix, pollen and alternaria) were conducted. In addition to this Birch was used as a country specific allergen in Norway. The studies were approved by the institutional review boards and an appropriate informed consent was obtained from each human subject. The clinical characteristics of the ascertained families are shown in Table 4 .
The following qualitative phenotypes were evaluated. (1) Asthma: A participating physician examined these patients and made a conclusive diagnosis of asthma from clinical information including common asthma symptoms, medication history, lung function and skin-pick tests. (2) BHR is defined as a positive methacholine response (X20% reduction in FEV 1 ) at or below 8 mg/ml of methacholine. (3) Atopic asthma: Atopic asthma is defined as having physician's diagnosis of asthma and at least one positive skin allergen test.
SNP selection and genotyping
We selected SNPs, regardless of the minor allele frequency (MAF) within exons and a MAF of 40.01 in the other regions. EDN1 gene is 10.4 kb in length. Eleven SNPs within EDN1 gene were selected from the NCBI SNP (http://www.ncbi.nlm.nih.gov/projects/SNP/) database and they covered the gene as uniformly as possible, on an average 1 SNP per kb. Their map positions were listed in Table 1 . These SNPs were genotyped by a modification of the single base chain extension (SBCE) assay previously described. 31 Parental genotype data were used to assess Hardy-Weinberg equilibrium using an exact method. 32 From each population, all SNPs were in Hardy-Weinberg equilibrium. The PedCheck program was used to detect Mendelian inconsistencies in the genotype data from each family population. 33 No genotyping inconsistencies were detected.
Statistical analysis
The software package FBAT version 1.7.3 34 was used for the family-based single-SNP association analysis with asthma, BHR and atopic asthma. Biallelic tests were performed for SNPs under an additive genetic model. The test of the null hypothesis was no linkage and no association. P-valueso0.05 from the analyses were considered the nominal significant levels. Considering that eleven SNPs were evaluated, the adjusted significant P-value is o0.00455 (that is, 0.05/11) after Bonferroni correction of multiple testing. Haplotype-based associations were tested using the HBAT extension function in the FBAT package with Monte Carlo sampling in the family data. 35 With a SNP sliding window approach (adjacent five SNPs), both global and haplotype-specific association statistics were reported. P-values o0.05 from the analyses were considered the nominal significant levels. Considering that seven (the number of window sliding) haplotypes were evaluated in our study, adjusted significant P-value is 0.00714 (that is, 0.05/7) based on a global P-value after Bonferroni correction of multiple testing. In consideration of high correlation among asthma, BHR and atopic asthma phenotypes, we chose not to correct for testing of the three phenotypes in order to avoid being overconservative.
The LD structure was assessed with the software package, Haploview version 4.0. 36 Strength of LD between pair of SNPs was calculated, and haplotype blocks were defined according to the criteria of Gabriel et al. Polymorphisms in the endothelin-1 G Zhu et al
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